StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Rotundine

HCID 5417
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
2934-97-6
Standard-SMILES
COc1cc2c(cc1OC)C1Cc3ccc(OC)c(OC)c3CN1CC2
InChIKey
AEQDJSLRWYMAQI-UHFFFAOYSA-N
Summenformel
C21H25NO4
Durchschnittliche Molmasse
355,4 g/mol
Monoisotopische Masse
355,17835828

Überblick

2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline is an alkaloid.

Namen und Bezeichner

Bevorzugter Name
Rotundine
IUPAC
2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline
Englischer Name
Tetrahydropalmatine
Summenformel
C21H25NO4
Molmasse
355.43

Namen und Synonyme

RotundineRefChem:9309042934-97-610097-84-4ROTUNDINUMD,L-Tetrahydropalmatine2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinolineTetrahydropalmatine, (+/-)-CHEMBL18789278F8583LNQ2,3,9,10-Tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[3,2-a]isoquinolineMFCD00214191
Weitere Namen anzeigen
L-TETRAHYDROPALMATINEDL-TETRAHYDROPALMATINEAKOS 208-04ROTUNDIN HYDRATERotundine CP2000TetrahydropalmatineTETRAHYDROPALMITINERafoxanide Impurity 5Tetrahydropalmatine-RM
Tetrahydropalmatine, dl-2,3,9,10-Tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquino[3,2-a]isoquinolinePalmatine, Tetrahydro derivative of2,3,9,10-Tetramethoxy-5,8,13,13a-tetrahydro-6H-isoquinolino[3,2-a]isoquinolineD-Tetrahydropalmatin; Rotundine; 5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-6H-dibenzo[a,g] quinolizineUNII-78F8583LNQRotundine [M+H]+(-)-Tetrahydropalmatine;L-Tetrahydropalmatine

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,2
Polarare Oberfläche (TPSA)
40,2 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
4
Schwere Atome
26
Formalladung
0
Komplexität
475

Experimentelle und physikochemische Eigenschaften

LogP2.6

Physikochemische Eigenschaften

Schmelzpunkt
155 ℃ · 155℃
Siedepunkt
482.9 · 482.9±45.0 °C(Predicted)
Dichte
1.23 · 1.23±0.1 g/cm3(Predicted)
storage temp.
Sealed in dry,Room Temperature
Löslichkeit
Chloroform (Slightly), Methanol (Slightly, Heated, Sonicated)
Aggregatzustand
Solid
pka
6.53 · 6.53±0.20(Predicted)
Farbe
White to Pale Yellow

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 2 (100%)

Sicherheitsdaten

hs_code
29339900

Chemie und Industrie

Pharmakologische Informationen

MeSH Pharmacological Classification · 6 Einträge

Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

A class of drugs that act by selective inhibition of calcium influx through cellular membranes.

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.

Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.

Anwendungen

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
2934-97-6
PubChem CID
5417
DTXSID
DTXSID20864207
ChEMBL
CHEMBL187892
ChEBI
CHEBI:91709
UNII
78F8583LNQ
EC Number
884-574-5
Nikkaji
J31.846I

VerwendenDL-Tetrahydropalmatine is the main active substance of the Chinese herb corydalis which induces hypotension and bradycardia in rats through the antagonism of striatal dopamine D2 receptor.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

8H-Dibenzo[a,g]quinolizin-8-one, 5,6,13,13a-tetrahydro-2,3,9,10-tetramethoxy-Dihydropalmatine